This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Aldosterone Blockade on Arterial Compliance (RAAS LAEI SAEI)

This study has been completed.
Information provided by:
Wolfson Medical Center Identifier:
First received: March 7, 2010
Last updated: March 26, 2010
Last verified: March 2010
The present study investigated the long-term (12 months) effect of spironolactone treatment on glucose homeostasis, metabolic parameters and vascular properties.

Condition Intervention Phase
Arterial Stiffness Arterial Elasticity Drug: Spironolactone Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Effect of Aldosterone Blockade on Metabolic Parameters and Arterial Compliance

Resource links provided by NLM:

Further study details as provided by Wolfson Medical Center:

Enrollment: 51
Study Start Date: May 2004
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Aldosteron blokade, Arterial stiffness, Glucose homeostasis Drug: Spironolactone
Spironolactone orally, at a dose of 50 mg/day for 12 months


Ages Eligible for Study:   45 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1. patients with type 2 diabetes mellitus

Exclusion Criteria:

  1. history of unstable angina, myocardial infarction (MI), cerebrovascular accident (CVA)
  2. major surgery within the six months preceding entrance to the study
  3. unbalanced endocrine disease
  4. any disease that might affect absorption of medications
  5. plasma creatinine >2.5 mg/dl
  6. elevation of liver enzymes to more that twice the upper normal limit
  7. plasma potassium levels >5.5 mg/dl
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01089309

Wolfson Medical Center
Holon, Israel, 58100
Sponsors and Collaborators
Wolfson Medical Center
  More Information Identifier: NCT01089309     History of Changes
Other Study ID Numbers: WolfsonMC-2004-388
Study First Received: March 7, 2010
Last Updated: March 26, 2010

Keywords provided by Wolfson Medical Center:
Aldosterone Blockade
Arterial elasticity
Glycemic control

Additional relevant MeSH terms:
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Natriuretic Agents processed this record on September 21, 2017